TD Cowen analyst Ryan Langston lowered the firm’s price target on Astrana Health (ASTH) to $35 from $40 and keeps a Buy rating on the shares. The firm said its forward estimates reflecttheir cautious outlook on Medicaid and the VBC environment.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ASTH:
- Astrana Health Inc. Reports Strong Q3 Earnings Amid Growth
- Astrana Health Reports Strong Revenue Growth in Q3 2025
- Strong Q3 Performance and Strategic Partnerships Justify Buy Rating for Astrana Health
- Astrana Health Reports Strong Q3 Revenue Growth
- Astrana Health reports Q3 EPS 1c vs. 33c last year